Resources
Search all resources on this page or select a tab to see publications, videos, audio, collections of related resources and more.
![Cover image for Australian Government response for the support for Australia’s thalidomide survivors]()
Support for Australia’s thalidomide survivors
Australian Government response to the Senate Community Affairs References Committee inquiry into support for Australia’s thalidomide survivors
![LSDPEP 8th meeting agenda – 19 February 2021 cover image]()
LSDPEP 8th meeting agenda – 19 February 2021
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 8th meeting on 19 February 2021.
![Cover image of LSDPEP 7th meeting agenda – 22 and 23 October 2020]()
LSDPEP 7th meeting agenda – 22 and 23 October 2020
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 7th meeting on 22 and 23 October 2020.
![Cover image of LSDPEP 6th meeting agenda – 25 and 26 June 2020]()
LSDPEP 6th meeting agenda – 25 and 26 June 2020
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 6th meeting on 25 and 26 June 2020.
![Cover image of LSDPEP 5th meeting agenda – 16 and 17 April 2020]()
LSDPEP 5th meeting agenda – 16 and 17 April 2020
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 5th meeting on 16 and 17 April 2020.
![Cover image of eliglustat (Cerdelga®) outcome statement]()
Life Saving Drugs Program – Eliglustat (Cerdelga®) outcome statement
This document states the outcome of Sanofi-Aventis Australia's application to include eliglustat on the Life Saving Drugs Program.
![Cover image of cerliponase alfa outcome statement]()
Life Saving Drugs Program – Cerliponase alfa (Brineura®) outcome statement
This document states the outcome of BioMarin's application to include cerliponase alfa on the Life Saving Drugs Program.
![Cover image of asfotase alfa outcome statement]()
Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement
This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.
![Cover image of HT1 initial application form]()
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for hereditary tyrosinaemia (type 1) for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Hereditary tyrosinaemia type 1![Cover image of PNH initial application form]()
Life Saving Drugs Program – Paroxysmal nocturnal haemoglobinuria – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for paroxysmal nocturnal haemoglobinuria for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuria![Cover image of Fabry disease initial application form]()
Life Saving Drugs Program – Fabry disease – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Fabry disease for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Fabry disease![Cover image of Pompe disease initial application form]()
Life Saving Drugs Program – Pompe disease – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Pompe disease![Cover image of MPS I initial application form]()
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS I for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type I (MPS I)![Cover image of MPS II initial application form]()
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS II for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type II (MPS II)![Cover image of MPS IVA initial application form]()
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS IVA for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type IVA (MPS IVA)![Cover image of MPS VI initial application form]()
Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS VI for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type VI (MPS VI)![Cover image of meningococcal vaccination certificate]()
Life Saving Drugs Program – Paroxysmal nocturnal haemoglobinuria – Meningococcal vaccination certificate
Treating physicians use this document to certify their patient's meningococcal vaccination status when applying or reapplying for eculizumab through the Life Saving Drugs Program.
Part of a collection: Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuria![Default image]( "Default image")
Life Saving Drugs Program resources – Mucopolysaccharidosis type I (MPS I)
A collection of resources for health professionals to help people with mucopolysaccharidosis type I (MPS I) access laronidase (Aldurazyme®) under the Life Saving Drugs Program.
![Default image]( "Default image")
Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuria
A collection of resources for health professionals to help people with paroxysmal nocturnal haemoglobinuria access eculizumab (Soliris®) under the Life Saving Drugs Program.
![Default image]( "Default image")
Life Saving Drugs Program resources – Mucopolysaccharidosis type II (MPS II)
A collection of resources for health professionals to help people with mucopolysaccharidosis type II (MPS II) access idursulfase (Elaprase®) under the Life Saving Drugs Program.
![Default image]( "Default image")
Life Saving Drugs Program resources – Mucopolysaccharidosis type IVA (MPS IVA)
A collection of resources for health professionals to help people with mucopolysaccharidosis type IVA (MPS IVA) access elosulfase alfa (Vimizim®) under the Life Saving Drugs Program.
![Default image]( "Default image")
Life Saving Drugs Program resources – Mucopolysaccharidosis type VI (MPS VI)
A collection of resources for health professionals to help people with mucopolysaccharidosis type VI (MPS VI) access galsulfase (Naglazyme®) under the Life Saving Drugs Program.
![Default image]( "Default image")
Life Saving Drugs Program resources – Pompe disease
A collection of resources for health professionals to help people with Pompe disease access alglucosidase alfa (Myozyme®) under the Life Saving Drugs Program.
![Default image]( "Default image")
Life Saving Drugs Program resources – Batten disease
A collection of resources for health professionals to help people with Batten disease access cerliponase alfa (Brineura®) under the Life Saving Drugs Program.
![Default image]( "Default image")
Life Saving Drugs Program resources – Gaucher disease
A collection of resources for health professionals to help people with Gaucher disease (type 1) access the following drugs under the Life Saving Drugs Program: imiglucerase (Cerezyme®), velaglucerase (VPRIV®), taliglucerase (Elelyso®) and miglustat (Zavesca®).
